Driving the Next Generation of Endocrinology Care

See our pipeline

VIEW OUR PUBLICATIONS

Singularly focused. Collectively driven.

SEE OUR VISION

Meet our inspiration

Empowering people to break through their disease.

Let’s build the future together

We are building the premier, endocrine-rooted global pharmaceutical company dedicated to improving the lives of patients. Are you fueled by an entrepreneurial passion for discovering, developing, and commercializing the next generation of therapies?

join us

What's new at Crinetics

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Crinetics announced that the U.S. FDA granted Orphan Drug Designation for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor…

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals reports second quarter 2025 financial results and provided a business update on August 7, 2025 at 4:30PM ET.

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Crinetics announced new data from its clinical development program evaluating once-daily, oral investigational PALSONIFYTM (paltusotine) in acromegaly at ENDO 2025.

view more news & media